Incyte Corp. has agreed to pay Novartis Pharma $280 million to settle a lawsuit over unpaid drug sale royalties, resolving a Southern District of New York breach of contract case the day it was ...

Novartis Pharma AG v. Incyte Corp. April 24, 2025 at 12:00 AM Email Share Font Size MediumLarge Print Case Digest Summary ...

Incyte and Novartis entered into a collaboration and license agreement in 2009. Write to Denny Jacob at [email protected] (END) Dow Jones Newswires May 14, 2025 08:45 ET (12:45 GMT) ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, ...

Q2 2025 Earnings Call Transcript July 29, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.04, expectations were $1.39. Operator: Greetings, and welcome to the Incyte Second ...

Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results, and provides a status update on the Company’s clinical development portfolio. "As I begin my tenure as ...

Incyte and Novartis have co-developed Jakafi since 2009 and Novartis is responsible for Jakafi's ex-US commercialization. We believe Dr. Riva will bring unique perspective on oncology drug ...

Tafasitamab sold to Incyte Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cash Shareholders benefit from attractive premium of ...

Stifel raised the firm’s price target on Incyte (INCY) to $75 from $73 and keeps a Hold rating on the shares. The firm says that a solid Jakafi beat/raise and steady/modestly-higher-than ...

Incyte INCY is set to give its latest quarterly earnings report on Tuesday, 2025-07-29. Here's what investors need to know before the announcement. Analysts estimate that Incyte will report an ...